Shintaro Narita, Takahiro Kimura, Shingo Hatakeyama, Kenichi Hata, Takafumi Yanagisawa, Shinya Maita, Shuji Chiba, Hiromi Sato, Soki Kashima, Atsushi Koizumi, Ryohei Yamamoto, Koichiro Takayama, Katsumi Okane, Toshiya Ishida, Yohei Horikawa, Teruaki Kumazawa, Jiro Shimoda, Takehiro Suzuki, Chikara Ohyama, Shin Egawa, Tomonori Habuchi
PURPOSE: We assessed clinical outcomes in patients with metastatic castration-sensitive prostate cancer (mCSPC) treated with two upfront therapies. METHODS: The medical records of 301 patients with mCSPC treated with androgen deprivation therapy plus upfront abiraterone acetate (ABI) or docetaxel (DOC) between 2014 and 2021 were retrospectively reviewed. Propensity score matching (PSM) was performed to compare survival outcomes. Subgroup analyses of risk factors for second progression were conducted...
September 2022: International Journal of Clinical Oncology